Aurora Cannabis Expands Global Medical Cannabis Market Presence

Highlights

• European medical business continues driving operational momentum across international markets.
• Record annual performance reflects disciplined business transformation initiatives.
• Medical cannabis strategy supports long-term international expansion plans.

Aurora Cannabis continues advancing its medical cannabis strategy through international expansion, operational discipline, and growing participation in regulated healthcare markets, strengthening its presence across the evolving global cannabis industry.

Aurora Cannabis (TSX:ACB) has gained renewed attention in Canada’s cannabis market after delivering record annual revenue and adjusted EBITDA for its latest fiscal year. The performance reflects the company’s continued shift toward a medical cannabis-led model, supported by disciplined operations, international market expansion, and rising demand across regulated healthcare channels. As the cannabis stocks segment evolves, Aurora’s focus on medical products and global markets continues to shape its business strategy within the TSX Smallcap Index landscape.

European Expansion Supports Growth

Europe remained one of the strongest contributors to Aurora's latest performance.

The company has steadily expanded its medical cannabis presence across several European countries where regulatory frameworks continue supporting prescription-based cannabis therapies. Demand for medical cannabis products has increased as healthcare systems broaden patient access and physicians become more familiar with approved treatment options.

Aurora (TSX:ACB) has invested in regulatory approvals, commercial partnerships, quality standards, and distribution capabilities that enable it to serve these expanding markets efficiently.

Its established international presence has helped position the company among Canadian cannabis producers participating in Europe's evolving medical cannabis industry.

Medical Cannabis Remains Core Focus

Rather than concentrating primarily on recreational cannabis, Aurora continues prioritising the medical cannabis segment.

Medical cannabis products generally require strict quality controls, pharmaceutical-grade manufacturing standards, and compliance with healthcare regulations. These requirements create specialised operating environments where established producers with regulatory expertise may strengthen long-term customer relationships.

Aurora's product portfolio serves patients requiring physician-authorised cannabis therapies while supporting healthcare providers through regulated distribution channels.

The company's continued investment in medical cannabis reflects its long-term focus on serving regulated healthcare markets both domestically and internationally.

Operational Discipline Supports Performance

Aurora's latest results also reflect several years of operational restructuring.

The company has streamlined production facilities, improved manufacturing efficiency, reduced operating complexity, and focused resources on business segments aligned with its long-term objectives.

These operational improvements have helped strengthen financial performance while creating a more disciplined operating model capable of supporting sustainable business development.

Efficiency initiatives continue playing an important role as cannabis producers adapt to changing market conditions and evolving consumer demand.

International Markets Create Opportunities

Global medical cannabis stocks markets continue expanding as more countries establish regulated access programmes.

International demand remains an important strategic priority for Aurora because many overseas markets continue developing healthcare frameworks that support prescription cannabis products.

The company's experience navigating complex regulatory environments provides valuable expertise when entering new jurisdictions requiring pharmaceutical-quality production, product traceability, and compliance with medical standards.

International diversification also broadens Aurora's market presence beyond Canada while supporting continued business development.

Industry Continues Evolving

The cannabis industry continues transitioning from rapid expansion toward greater operational discipline.

Companies increasingly focus on product quality, manufacturing efficiency, regulatory compliance, and sustainable business practices rather than production scale alone.

Aurora's (TSX:ACB) business strategy reflects this shift by emphasising medical cannabis, international expansion, and operational excellence.

The company's latest fiscal performance highlights how disciplined execution can support business stability within a highly regulated and competitive industry.

Innovation Remains Important

Research and product development continue supporting Aurora's (TSX:ACB) long-term direction.

The company remains focused on developing cannabis products designed for medical applications while maintaining quality standards expected within regulated healthcare markets.

As patient demand evolves and clinical understanding expands, innovation across formulations, delivery methods, and patient care solutions remains an important component of future product development.